Evaluation of the Effectiveness of Eradication Therapy Based on Potassium-Competitive Acid Blockers in Patients with Helicobakter Pylori Associated Chronic Gastritis

Article Sidebar

PDF
Published: May 29, 2023
Keywords:
Vonoprozane potassium- competitive acid blocker helicobacter pylori chronic gastritis eradication

Main Article Content

Karimov M.M
GU "Republican specialized scientific and practical medical center for therapy and medical rehabilitation" Tashkent Medical Academy
Zufarov P.S
GU "Republican specialized scientific and practical medical center for therapy and medical rehabilitation" Tashkent Medical Academy
Sobirova G.N
GU "Republican specialized scientific and practical medical center for therapy and medical rehabilitation" Tashkent Medical Academy

Abstract

The article presents data on the results of a comparative study of the clinical and antihelicobacteric efficacy of two schemes of eradication therapy in 60 patients with HP-associated chronic gastritis. The main group of patients received eradication therapy consisting of Vonoprozane, amoxicillin, clarithromycin and bismuth tricalium decitrate for 10 days. In the second group of patients with chronic gastritis, Esomeprazole was used as an antisecretory drug against the background of similar therapy. The results of the study showed that in the first group of patients, the dynamics of acid suppression under the influence of vonoprase was significantly higher compared to Esomeprazole. Also, in the main group of patients, the rate of eradication of HP infection was 93%, whereas in the group of patients taking Esomeprazole, this indicator was 80%.

Article Details

How to Cite
Karimov M.M, Zufarov P.S, & Sobirova G.N. (2023). Evaluation of the Effectiveness of Eradication Therapy Based on Potassium-Competitive Acid Blockers in Patients with Helicobakter Pylori Associated Chronic Gastritis. Journal of Coastal Life Medicine, 11(2), 1481–1483. Retrieved from https://www.jclmm.com/index.php/journal/article/view/1185
Issue
Vol. 11: Number 2, 2023
Section
Articles

References

Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. //Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. /Gut. 2007; 56:772-781. doi:10.1136/gut.2006.101634.

Malfertheiner P, Megraud F , O'Morain CA, et al .//Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report/ Gut 2017;66:6–30.doi:10.1136/gutjnl-2016-312288.

Sugano K, Tack J, Kuipers EJ, et al Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64:135367.

Каримов М.М., Собирова Г.Н., Саатов З.З., Исламова Ш.З., Рустамова С.Т. /Распространенность и молекулярно-генетические характеристики H. Pylori в Узбекистане//Эффективная фармакотерапия, 28(15) 2019. Москва. С.48-51.

Graham DY, Dore MP. //Helicobacter pylori therapy: a paradigm shift/Expert Rev Anti Infect Ther. 2016;14(6):577-585.

Sobirova G.N., Karimov M.M., Abdullaeva U.K., Aslonova I.J., Tulyzganova F.M. //Serological Diagnostics of atrophy of the gastric mucosa / American Journal of Medical Science and Pharmaceutical Research 2020, 02 (12): 118-124.

Malfertheiner P., Megraud F., Rokkas //Th. et all. 4 Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report/Gut. 2022 Aug 8; gutjnl-2022-327745.

Iwakiri K, Sakurai Y, Shiino M, Okamoto H, Kudou K, Nishimura A, Hiramatsu N, Umegaki E, Ashida K. //A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis/ Therap Adv Gastroenterol. 2017 Jun;10(6):439-451.

Mori H, Suzuki H. //Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker/ J Neurogastroenterol Motil. 2019 Jan 31;25(1):6-14. doi: 10.5056/jnm18139.

Akazawa Y, Fukuda D, Fukuda Y.//Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence/Therap Adv Gastroenterol. 2016;9(6):845-852. doi:10.1177/1756283X16668093.

Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. //Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study/ Gut. 2016;65(9):1439-1446. doi:10.1136/gutjnl-2015-311304.

Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. //The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPIBased Low-Dose Clarithromycin Triple Therapy/ Am J Gastroenterol. 2016;111(7):949-956. doi:10.1038/ajg.2016.182.